Rectal cancer
Benefits of a combination of chemotherapy tablets and injectable targeted therapy versus using a targeted therapy tablet alone in colorectal cancer patients
Who can joinAsk the trial team
AgeAsk the trial team
Kind of studyPhase 3: compared with usual treatment
What it testsA medicine
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Contact hospital
The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.
Tata Memorial HospitalMumbaiDirections ↗
Registry summary (technical)
TAS-102 plus Bevacizumab vs Regorafenib in chemotherapy-refractory advanced colorectal cancers - a randomized non-blinded two-arm Phase III prospective clinical trial (TARt study).
Sponsor: Tata Memorial Hospital
CTRI/2023/04/051850 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 1 Jun 2026 · read by us 5 Nov 2026